Metformina + Sitagliptina Alter

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Alter, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. GNH USA supplies Metformina + Sitagliptina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Alter is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways. - Type 2 diabetes mellitus: lowers fasting plasma glucose levels. - Type 2 diabetes mellitus: reduces hemoglobin A1c (HbA1c) concentrations. - Type 2 diabetes mellitus: improves post‑prandial glucose control.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Headache: transient cranial discomfort. - Upper respiratory tract infection: mild cold‑like symptoms. - Abdominal discomfort: cramping or pain.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Hepatic failure: impaired liver function. - Allergic reactions: rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating therapy, consider patient‑specific factors and monitor for complications. - Renal impairment: assess kidney function and adjust dose if needed. - Hepatic impairment: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in patients with severe renal or hepatic disease. - Alcohol consumption: limit intake to reduce acidosis risk. - Pregnancy and lactation: safety not established; weigh benefits versus risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metformina + Sitagliptina Alter can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Other biguanides (e.g., phenformin): increased risk of lactic acidosis. - Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis. - Strong CYP3A4 inducers (e.g., rifampin): may reduce sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Cimetidine: can raise metformin plasma concentrations. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (especially thiazides): may affect renal clearance of metformin.